Thelansis

  Dizal, a biopharmaceutical company dedicated to the development of novel treatments for cancer and immunological diseases, has announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for sunvozertinib. This designation is for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), who have not received prior systemic therapies. Publish Date: 13-10-2024   Source: Dizal Pharma Advanced metastatic NSCLC has shown a significant increase in survival rates with chemotherapy compared to best supportive care alone. Subsequent advancements included improved response rates with third-generation agents such as paclitaxel, docetaxel, vinorelbine, and gemcitabine, surpassing the efficacy of second-generation treatments like ifosfamide, ...

 Advanced metastatic NSCLC has shown a significant increase in survival rates with chemotherapy compared to best supportive care alone. Subsequent advancements included improved response rates with third-generation agents such as paclitaxel, docetaxel, vinorelbine, and gemcitabine, surpassing the efficacy of second-generation treatments like ifosfamide, mitomycin, and vindesine alongside standard platinum chemotherapy in doublet regimens. Current standard practice in treating metastatic NSCLC involves targeting anaplastic lymphoma kinase (ALK) with tyrosine kinase inhibitors (TKIs), particularly for ALK-positive patients confirmed through standard FISH (Fluorescence in situ hybridization) technique or for ROS1 positive patients. Alectinib has emerged as the preferred first-line agent due to its superior progression-free survival (PFS) demonstrated in direct comparison with crizotinib. The treatment landscape for advanced NSCLC has become increasingly complex with the advent of newe...

 Non-Small Cell Lung Cancer (NSCLC) is the most common form of lung cancer. Early-stage NSCLC accounts for approximately 18% of the cases. Most of these patients are treated with curative intent and often require multimodality therapy. The 5-year overall survival (OS) ranges from 50% for stage IA disease to 15% for stage IIIA NSCLC. Several clinical trials have demonstrated improved survival with postoperative chemotherapy in selected patients who undergo complete surgical resection. Available evidence supports the use of adjuvant chemotherapy for stage II and stage IIIA, but not for stage IA NSCLC. The standard of care for patients with stage I, II and IIIA, non-small-cell lung cancer (NSCLC), is surgical resection. Following resection, patients may be offered adjuvant systemic therapy. ·        HER2 mutations and HER2 amplifications have been reported in approximately 2% to 3% and 2% to 5% of lung adenocarcinomas, respectively. Thelansis’s “Advan...